A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The present trial will use an open label design to investigate the effect of BI 144807 on
central 1-mm retinal thickness and presence of neovascular leakage in newly diagnosed wAMD
patients. A further objective is to collect data on adverse events, vital signs, ECG and
clinical laboratory parameters of BI 144807 in the same patient group.